Simcere Pharma (2096 HK): Sanbexin Increase Market Share; Prospective Pipeline, Approvals Holds Key
Simcere Pharma reported 28% YoY revenue growth to RMB 4.6B, driven by neuroscience and autoimmune segments. Licensing deals, pending approvals and...
91 Views
Primer: Simcere Pharmaceutical (2096 HK) - Aug 2026
Transition to Innovation Powerhouse: Simcere is successfully transitioning from a generic drug manufacturer to an R&D-driven pharmaceutical...
93 Views
3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?
3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...
394 Views
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
103 Views
China Healthcare Weekly Wrap (31 Aug - 4 Sep)
Key news this week: 1) licensing deals from Hutchmed and Simcere; 2) Hengrui's data of heart drugs in ESC. Separately, pelacarsen from Novartis...
137 Views